NCT01480609View on ClinicalTrials.gov

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 24, 2012

Study Completion Date

April 24, 2012

Conditions

Epilepsy

Interventions

DRUG

Retigabine / Ezogabine

Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis